While calcium antagonists are well established for the treatment of hypertension there are significant differences in the pharmacodynamic profiles between subgroups of these drugs. In elderly hypertensive patients who have an increased incidence of adverse effects to antihypertensive treatment it is desirable that a calcium antagonist has a gradual onset and long duration of action and causes minimal activation of counterregulatory systems. Lacidipine is a third-generation dihydropyridine calcium antagonist that is effective in the treatment of elderly patients with essential hypertension 1 and is characterised by its lipophilic properties and unique interaction with cell membrane calcium receptors. 2 There is however, little information on the effect of the long-acting, thirdgeneration agents on adrenergic and non-adrenergic endogenous vasoconstrictor mechanisms 3 or activity of vasoactive hormone systems. 4 We are also unaware of any study that has investigated the haemorheological effects of lacidipine.
We carried out a study in 18 elderly patients with essential hypertension with the aim of investigating the affects of lacidipine on the activity of the reninangiotensin-aldosterone system, plasma levels of natriuretic peptides and haemorheological profile. The study included two separate phases. The first phase was a placebo-controlled, cross-over design consisting of two 4-week treatment periods preceded by a 3-week placebo run-in period and separated by a 2-week washout period without medication. were measured by radioimmunoassay techniques every 2 weeks. Intra-assay coefficients of variation were less than 9% for all these assays. Haemorheology analyses were carried out at the start and end of the treatment periods and included measurements of whole blood viscosity 10 and plasma viscosity.
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Red blood cell (RBC) deformability was assessed by determining the relative whole blood viscosity at high shear rate 12 and also by a filtration technique using a St George's Filtrometer (Carri-Med, Luton, UK). 13 The second phase of the study consisted of an open, 48-week study of lacidipine only, during which the haemorheology profile was measured at 12, 24 and 48 weeks.
The data was analysed using the SAS ® system for Windows 6.10. The principal assessment of efficacy was based on a cross-over analysis, allowing for carry-over period and treatment effects. The haemorheology data from the open extension phase was analysed using analysis of variance and covariance with repeated measures using the data obtained at the final visit of the comparative phase as the covariate.
Fifteen of the 18 patients completed the study and the data of these patients are summarised in Table 1 . The study confirmed that lacidipine is an effective antihypertensive agent in elderly patients. Mean systolic and diastolic ambulatory blood pressure recordings were consistently lower during treatment with lacidipine compared with placebo with this effect being most apparent during the normal circadian increase in morning blood pressure (Figure 1 ). Lacidipine also reduced the variability in daytime systolic blood pressure whilst preserving the diurnal blood pressure rhythm, an effect that has been described previously. 14, 15 Four weeks administration of lacidipine did not cause activation of the renin-angiotensin IIaldosterone axis. While there are conflicting reports on the effect of different calcium antagonists on the activity of this system [16] [17] [18] [19] [20] it is generally accepted that calcium antagonists with especially potent peripheral vasodilatory activity stimulate renin release 4 and that the basal plasma concentration of renin is an important determinant of the antihypertensive efficacy of the drug. 20 In addition, it appears that any alteration in plasma renin activity is more likely an indirect consequence of blood pressure reduction rather than a direct action of the drug on hormone release mechanisms. 16 Lacidipine also did not alter plasma levels of natriuretic peptides compared with placebo. Other studies on calcium antagonists have shown that reducing blood pressure may be associated with a decrease in ANP and BNP concentrations probably as an result of reduced cardiac load and stretch. 21 Furthermore, it has been suggested that calcium entry into cardiac myocytes can be an important regulator of ANP secretion. 22 The finding in our study that 4 weeks' administration of lacidipine had no effect on ANP or BNP concentration suggest that any alterations in cardiac chamber stretch and change in cardiomyocyte intracellular calcium-induced modification of cardiac natriuretic peptide secretion was minimal. This, however, does not exclude a potential effect of the drug on ANP or BNP secretion under other circumstances such as exercise or myocardial infarction.
In agreement with numerous other studies on calcium antagonists 23 we observed that long-term treatment with lacidipine was associated with an improvement in intrinsic RBC rheology. This change was observed as a statistically significant decrease in relative high shear rate whole blood viscosity and a trend of increased filtration rate of RBCs through pores with dimensions similar to that of the microcirculation. These effects, if real, were most likely due to the drug maintaining a low intracellular calcium concentration in the RBCs, that in conjunction with adequate ATP stores, resulted in optimal deformability of the cells.
In summary, this study showed that short-term treatment with the dihydropryridine calcium antagonist in elderly patients with essential hypertension was associated with improved blood pressure control compared with placebo and that the drug did not cause activation of the reninangiotensin II-aldosterone axis or stimulate increased plasma levels of ANP or BNP. 
